1. EHL Factor Products in Hemophilia: An Update for Pharmacists and Lab Technicians

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

3. EHL Factor Products in Hemophilia

4. Hemophilia

5. Hemophilia (cont)

6. Categorization of the Severity of Hemophilia

7. Recombinant Factor Generations

8. rFVIII Products First and Second Generation

9. rFVIII Products Third Generation

10. rFIX Products

11. Half-Life of Standard Factor Products

12. Fc Fusion Clotting Proteins

13. Fc Fusion Clotting Proteins (cont)

14. PEGylated and GlycoPEGylated Clotting Proteins

15. PEGylated and GlycoPEGylated Clotting Proteins (cont)

16. Albumin Fusion Clotting Proteins

17. FVIII Dosing

18. FIX Dosing

19. Inhibitors

20. Conclusions

21. Monitoring EHL Factor Products

22. Monitoring

23. Laboratory Monitoring Overview

24. OSA

25. CSA

26. Differences Between OSA and CSA

27. Patient Case

28. Discrepancies Between OSA and CSA

29. Discrepancies Between OSA and CSA (cont)

30. Discrepancies Between OSA and CSA for Modified FVIII Products

31. Discrepancies Between OSA and CSA for Modified FIX Products

32. Discrepancies Between OSA and CSA for Modified Factor Products

33. Strategies in Overcoming Assay Discrepancies

34. Pharmacist Role in Laboratory Monitoring

35. Clinical Monitoring of Modified Factor Products

36. Treatment Log

37. Management of Bleeding Episodes

38. Pharmacist Role in Clinical Monitoring

39. Abbreviations